Tyra Biosciences, Inc. (TYRA) Insider Trading Activity

NASDAQ$28.65
Market Cap
$1.71B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
820 of 853
Rank in Industry
473 of 492

TYRA Insider Trading Activity

TYRA Median Price and Trade Amounts History Chart

Statistics of Insider Transactions

Amount of Insider Buys and Sells

Buys
$0
0
0
Sells
$10,589,832
11
100

Related Transactions

KAPLAN GILLAdirector
0
$0
1
$528,506
$-528,506
Bensen DanielChief Operating Officer
0
$0
8
$4.81M
$-4.81M
MORE ROBERT Jdirector
0
$0
2
$5.25M
$-5.25M

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.

Insider Activity of Tyra Biosciences, Inc.

Over the last 12 months, insiders at Tyra Biosciences, Inc. have bought $0 and sold $10.59M worth of Tyra Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Tyra Biosciences, Inc. have bought $54.29M and sold $8.97M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 11,813 shares for transaction amount of $119,666 was made by RA CAPITAL MANAGEMENT, L.P. () on 2025‑06‑16.

List of Insider Buy and Sell Transactions, Tyra Biosciences, Inc.

2026-03-25SaleKAPLAN GILLAdirector
14,295
0.0268%
$36.97
$528,506
-12.99%
2026-02-12SaleBensen DanielChief Discovery Officer
8,000
0.0169%
$32.87
$262,965
+11.92%
2026-01-12SaleBensen DanielChief Discovery Officer
8,000
0.0149%
$28.52
$228,186
+11.02%
2025-12-19SaleMORE ROBERT Jdirector
10,000
0.0184%
$25.00
$250,000
+23.09%
2025-12-12SaleBensen DanielChief Discovery Officer
8,000
0.015%
$22.64
$181,159
+37.76%
2025-11-21SaleMORE ROBERT Jdirector
246,871
0.4436%
$20.25
$5M
+46.43%
2025-11-19SaleBensen DanielChief Operating Officer
49,956
0.0919%
$16.32
$815,297
+85.89%
2025-11-18SaleBensen DanielChief Operating Officer
75,633
0.142%
$16.07
$1.22M
+92.52%
2025-11-17SaleBensen DanielChief Operating Officer
20,072
0.0383%
$16.18
$324,798
+94.15%
2025-11-14SaleBensen DanielChief Operating Officer
110,228
0.2122%
$16.02
$1.77M
+96.19%
2025-11-13SaleBensen DanielChief Operating Officer
1,111
0.0021%
$16.00
$17,780
+97.82%
2025-06-18SaleKAPLAN GILLAdirector
9,568
0.0185%
$9.78
$93,596
+141.79%
2025-06-17SaleKAPLAN GILLAdirector
10
<0.0001%
$10.35
$104
+137.85%
2025-06-16SaleKAPLAN GILLAdirector
6,814
0.013%
$10.38
$70,726
+123.09%
2025-06-16PurchaseRA CAPITAL MANAGEMENT, L.P.
11,813
0.022%
$10.13
$119,666
+123.09%
2025-06-13SaleKAPLAN GILLAdirector
15,000
0.0279%
$10.31
$154,583
+116.83%
2025-06-13PurchaseRA CAPITAL MANAGEMENT, L.P.
120,167
0.2214%
$10.20
$1.23M
+116.83%
2025-06-12SaleKAPLAN GILLAdirector
30,000
0.0564%
$10.31
$309,255
+118.78%
2025-06-12PurchaseRA CAPITAL MANAGEMENT, L.P.
31,307
0.0582%
$10.20
$319,331
+118.78%
2025-06-09PurchaseRA CAPITAL MANAGEMENT, L.P.
186,850
0.3495%
$10.19
$1.9M
+116.96%
Total: 117
*Gray background shows transactions not older than one year

Insider Historical Profitability

29.35%
MORE ROBERT Jdirector
3823425
6.4084%
$109.54M12
<0.0001%
Bensen DanielChief Discovery Officer
146981
0.2464%
$4.21M049
KAPLAN GILLAdirector
28231
0.0473%
$808,818.1506
RA CAPITAL MANAGEMENT, L.P.
10259291
17.1954%
$293.93M80
+79.87%
Boxer Capital, LLC10 percent owner
6448359
10.808%
$184.75M20
<0.0001%
Alta Partners NextGen Fund II Management, LLC10 percent owner
4080296
6.8389%
$116.9M10
<0.0001%
Harris ToddPresident and CEO
1355927
2.2726%
$38.85M031
Cormorant Asset Management, LP
1069932
1.7933%
$30.65M10
<0.0001%
Kjellson Nina Sdirector
443885
0.744%
$12.72M013
MVA Investors, LLC10 percent owner
22527
0.0378%
$645,398.5502
Fuhrman AlanChief Financial Officer
12849
0.0215%
$368,123.8510
<0.0001%
*Gray background shows insiders who have made transactions during last year

Historical Insider Profitability vs. Competitors

$8,217,280
112
46.33%
$1.68B
$61,893,001
38
19.63%
$1.47B
$530,111,731
35
8.69%
$1.57B
$28,907,358
35
41.41%
$1.97B
$4,431,947
22
36.10%
$1.6B
$135,656,796
20
30.67%
$1.68B
$24,007,605
16
-20.65%
$1.79B
Tyra Biosciences, Inc.
(TYRA)
$108,588,651
14
29.35%
$1.71B
$48,220,484
14
2.13%
$1.78B
$81,819,942
13
-52.16%
$1.49B
$3,101,788
13
41.97%
$1.82B
$278,247,340
12
58.08%
$1.92B
$94,976,497
10
-10.72%
$1.92B
$4,623,072
7
11.07%
$1.51B
$47,238,722
7
-23.48%
$1.78B
$1,011,808
4
52.60%
$1.68B
$103,599,972
2
-36.81%
$1.9B
$33,624,000
2
-50.37%
$1.52B
$23,993,224
1
9.82%
$1.84B

TYRA Institutional Investors: Active Positions

Increased Positions72+55.81%6M+10.45%
Decreased Positions53-41.09%4M-7.98%
New Positions30New3MNew
Sold Out Positions14Sold Out783,658Sold Out
Total Postitions148+14.73%57M+2.47%

TYRA Ownership Change vs Market

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
Ra Capital Management, L.P.$326,801.0023.02%12.2M00%2025-09-30
Alta Partners Management Company, L.P.$109,311.007.7%4.08M00%2025-09-30
Nextech Invest, Ltd.$108,657.007.65%4.06M00%2025-09-30
Bvf Inc/Il$97,778.006.89%3.65M-294,400-7.46%2025-09-30
Canaan Partners Xi Llc$96,661.006.81%3.61M00%2025-09-30
Commodore Capital Lp$90,416.006.37%3.38M+275,000+8.87%2025-09-30
Tcg Crossover Management, Llc$77,640.005.47%2.9M00%2025-09-30
Janus Henderson Group Plc$77,016.005.42%2.87M+18,514+0.65%2025-09-30
Vestal Point Capital, Lp$64,966.004.58%2.42M-230,000-8.66%2025-09-30
Kynam Capital Management, Lp$62,421.004.4%2.33M00%2025-09-30

Financial Ratios

Summary
Comparison with Competitors

Price to Earnings

Price/Earnings to Growth

Price to Sales

Price to Book

Price/Free Cash Flow

Analyst Recommendations

Analyst Price Targets

Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.